IgGenix
PrivateLast Round
Series B
Feb 6, 2023
Total Funding Raised
$75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
IgGenix is a biotechnology company that develops an antibody-based therapeutic platform designed to accelerate clinical responses to allergies by engineering antibodies that effectively capture allergens and enhance immune modulation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IgGenix Comparables
Compare IgGenix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mabylon AG | 83% | |
| Aravax | 79% | |
| Roche Holding | 74% | |
IgGenix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 6, 2023 | ||||
| Series A Extension | Jul 27, 2021 | ||||
| Series A | Aug 4, 2020 |
Key People
Founding team and executive leadership
IgGenix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AllerFund | Series A Extension, Series B |
| Medical Incubator Japan | Series B |
| Khosla Ventures | Series B, Series A, Series A Extension |
| Alexandria Venture Investments | Series A Extension, Series B |
| ShangBay Capital | Series A Extension |
| Alexandria Venture Investments | Series A Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors grew 36% MoM, reaching 1.8K.
- Feb 10, 2025
Will present Alpha-gal Syndrome discovery at 2025 AAAAI / WAO Joint Congress.
IgGenix Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about IgGenix's valuation, stock price, and market status.